General Information of the Compound
| Compound ID |
CP0368828
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
US9034874, 1.5
Show/Hide
|
||||||||||||||||||
| Synonyms |
PMID29334795-Compound-45
Piperazine carbamate/urea derivative 7
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C19H29N5O3
|
||||||||||||||||||
| Molecular Weight |
375.473
|
||||||||||||||||||
| Canonical SMILES |
Cn1nc(ccc1=O)N1CCC(CC1)OC(=O)N1CCN(CC1)C1CCC1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C19H29N5O3/c1-21-18(25)6-5-17(20-21)23-9-7-16(8-10-23)27-19(26)24-13-11-22(12-14-24)15-3-2-4-15/h5-6,15-16H,2-4,7-14H2,1H3
Show/Hide
|
||||||||||||||||||
| InChIKey |
BVUJMFFRMZRNAT-UHFFFAOYSA-N
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Clinical Information about the Compound
Drug 1 ( Piperazine carbamate/urea derivative 7 )
| Drug Name | Piperazine carbamate/urea derivative 7 | ||
|---|---|---|---|
| Company | NOVARTIS AG AUBERSON, Yves BOCK, Mark Gary BRAGA, Dario CURZI, Marco DODD, Stephanie Kay GIAFFREDA, Stefano Luca JIANG, Haiyang KARPINSKI, Piotr TROXLER, Thomas J. WANG, Tielin WANG, Xiaoyang ZHANG, XuechuNOVARTIS AG | ||
| Target(s) | |||